EGFR and non-small cell lung carcinoma: Unlike EGFR-tyrosine kinase inhibitors, antiangiogenic agents combined with conventional chemotherapy have demonstrated clinical benefit in NSCLC (Herbst et al, 2007), and recent studies have demonstrated the safety of enzastaurin combination with cytotoxic drugs (Rademaker-Lakhai et al, 2007), including pemetrexed (Hanauske et al, 2006).